دورية أكاديمية
أعرض في EDS

Prognostic Value of Hematological Parameters in Oral Squamous Cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Prognostic Value of Hematological Parameters in Oral Squamous Cell Carcinoma.
المؤلفون: Trevisani LFM; Programa de Pós-Graduação em Anestesiologia, Ciências Cirúrgicas e Medicina Perioperatória, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-903, Brazil., Kulcsar IF; Instituto do Câncer do Estado de São Paulo (Icesp), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil., Kulcsar MAV; Head and Neck Surgery Department, Instituto do Câncer do Estado de São Paulo (Icesp), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil., Dedivitis RA; Head and Neck Surgery Department, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil., Kowalski LP; Head and Neck Surgery Department, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil., Matos LL; Head and Neck Surgery Department, Instituto do Câncer do Estado de São Paulo (Icesp), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil.; Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo 05652-000, Brazil.
المصدر: Cancers [Cancers (Basel)] 2023 Oct 31; Vol. 15 (21). Date of Electronic Publication: 2023 Oct 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Introduction: Oral squamous cell carcinoma (OSCC) remains a significant public health concern. The variables utilized to determine appropriate treatment for this disease also represent its most unfavorable prognostic factors, with these parameters solely determined by the neoplasm and its behavior. However, a lack of well-established indices is evident in the literature that specifically relate to the patient and indicate a worse prognosis.
Objective: To assess the prognostic impact of hematological indices in patients with OSCC.
Methods: This retrospective cohort study included patients with oral squamous cell carcinoma (OSCC) who underwent curative-intent treatment. Treatment encompassed surgery, followed by adjuvant therapy, as necessary. Laboratory tests were conducted immediately prior to surgery, and demographic information was obtained from medical records.
Results: The cohort comprised 600 patients, with 73.5% being male subjects. Adjuvant treatment was recommended for 60.3% of patients. Throughout the follow-up period, 48.8% of participants died. Univariate analysis indicated that perineural invasion, angiolymphatic invasion, pT4 tumors, lymph node metastases, extranodal extravasation, RDW > 14.3%, NLR (neutrophil-lymphocyte ratio) > 3.38, PLR (platelet-lymphocyte ratio) > 167.3, and SII (systemic inflammatory/immune response index) > 416.1 were factors associated with increased mortality. These threshold values were established through ROC curve analysis. In the multivariate analysis, angiolymphatic invasion (HR = 1.43; 95% CI: 1.076-1.925; p = 0.014), pT4a/b tumors (HR = 1.761; 95% CI: 1.327-2.337; p < 0.001), extranodal extravasation (HR = 1.420; 95% CI: 1.047-1.926; p = 0.024), and RDW (HR = 1.541; 95% CI: 1.153-2.056; p = 0.003) were identified as independent risk factors for decreased overall survival.
Conclusions: RDW > 14.3% was proven to be a reliable parameter for assessing overall survival in patients with OSCC. Further studies are required to evaluate the clinical applicability of other hematological indices.
References: Laryngoscope. 2018 Sep;128(9):2050-2055. (PMID: 29399797)
Arch Intern Med. 2009 Mar 23;169(6):588-94. (PMID: 19307522)
Braz J Otorhinolaryngol. 2022 Nov-Dec;88 Suppl 4:S89-S97. (PMID: 35277368)
Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1663-1670. (PMID: 29651542)
Rep Pract Oncol Radiother. 2021 Dec 30;26(6):1010-1018. (PMID: 34992875)
Oncotarget. 2017 Feb 28;8(9):16027-16035. (PMID: 27926498)
Oncol Res Treat. 2019;42(12):665-677. (PMID: 31550732)
CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848)
J Oral Maxillofac Surg. 2013 Apr;71(4):775-85. (PMID: 23265849)
Crit Rev Clin Lab Sci. 2015;52(2):86-105. (PMID: 25535770)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
Front Oncol. 2022 Jun 24;12:899518. (PMID: 35814369)
Cancer. 2020 Mar 15;126(6):1163-1165. (PMID: 31774548)
J Cancer. 2018 Jun 6;9(13):2295-2301. (PMID: 30026824)
Semin Oncol. 2010 Apr;37(2):e9-18. (PMID: 20494694)
Oncotarget. 2016 Jul 5;7(27):42650-42660. (PMID: 27223088)
Clin Chem Lab Med. 2015 Apr;53(5):823-7. (PMID: 25860865)
Cancer Manag Res. 2018 Sep 17;10:3611-3618. (PMID: 30271209)
J Am Coll Cardiol. 2007 Jul 3;50(1):40-7. (PMID: 17601544)
Br J Cancer. 2011 Jun 28;105(1):93-103. (PMID: 21629244)
Front Oncol. 2019 Apr 16;9:271. (PMID: 31041191)
Oral Oncol. 2019 Mar;90:115-121. (PMID: 30846169)
J Craniomaxillofac Surg. 2016 Sep;44(9):1414-21. (PMID: 27485718)
PLoS One. 2012;7(5):e37644. (PMID: 22649548)
Nephrol Dial Transplant. 2012 Feb;27(2):589-94. (PMID: 21712489)
Asian Pac J Cancer Prev. 2015;16(2):753-6. (PMID: 25684520)
Eur Arch Otorhinolaryngol. 2017 Jan;274(1):535-542. (PMID: 27520567)
Otolaryngol Head Neck Surg. 2018 Jul;159(1):51-58. (PMID: 29436280)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
COPD. 2013 Aug;10(4):416-24. (PMID: 23537076)
Acta Otorhinolaryngol Ital. 2014 Dec;34(6):389-93. (PMID: 25762830)
J Cancer. 2019 Jul 10;10(18):4305-4317. (PMID: 31413750)
JCO Precis Oncol. 2019;3:. (PMID: 31840130)
Clin Lab Haematol. 1991;13(2):222-3. (PMID: 1934934)
J Clin Med Res. 2013 Apr;5(2):121-6. (PMID: 23518817)
BMC Med Res Methodol. 2017 Apr 7;17(1):53. (PMID: 28388943)
Braz J Otorhinolaryngol. 2015 May-Jun;81(3):248-54. (PMID: 25890681)
N Engl J Med. 2005 Mar 10;352(10):1011-23. (PMID: 15758012)
Laryngoscope. 2018 Dec;128(12):2740-2744. (PMID: 29756295)
Braz J Otorhinolaryngol. 2015 Jan-Feb;81(1):44-9. (PMID: 25458257)
Oncologist. 2000;5 Suppl 2:13-8. (PMID: 10896324)
Eur Arch Otorhinolaryngol. 2017 Nov;274(11):3985-3992. (PMID: 28866825)
Br J Oral Maxillofac Surg. 2017 Nov;55(9):911-916. (PMID: 28918183)
Am J Cardiol. 2012 Jan 1;109(1):128-34. (PMID: 21958741)
Oral Oncol. 2017 Sep;72:90-97. (PMID: 28797467)
Adv Clin Chem. 2017;82:105-197. (PMID: 28939210)
J Interferon Cytokine Res. 1998 Aug;18(8):555-9. (PMID: 9726435)
Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40. (PMID: 9639472)
Diabetologia. 2012 Jan;55(1):226-35. (PMID: 22002006)
Rev Assoc Med Bras (1992). 2011 Mar-Apr;57(2):171-6. (PMID: 21537703)
BMC Cancer. 2020 Jun 17;20(1):568. (PMID: 32552873)
Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2869-2878. (PMID: 30251123)
Front Oncol. 2020 Mar 11;10:341. (PMID: 32219070)
J Oral Pathol Med. 2022 Jan;51(1):39-51. (PMID: 34797592)
Ann Otol Rhinol Laryngol. 2022 Oct;131(10):1102-1108. (PMID: 34715735)
PLoS One. 2016 Sep 22;11(9):e0163282. (PMID: 27658208)
معلومات مُعتمدة: 2016/01740-6 São Paulo Research Foundation; 800605/2018-7 National Council for Scientific and Technological Development
فهرسة مساهمة: Keywords: RDW; oral squamous cell carcinoma; prognosis
تواريخ الأحداث: Date Created: 20231114 Latest Revision: 20231117
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10649982
DOI: 10.3390/cancers15215245
PMID: 37958419
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15215245